Increased urinary cystatin C indicated higher risk of cardiovascular death in a community cohort

Helmersson‐Karlqvist, Johanna; Ärnlöv, Johan; Carlsson, Axel C.; Härmä, Johan; Larsson, Anders

doi:10.1016/j.atherosclerosis.2014.02.020

Cited by 13 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cystatin C level was strongly linked with mortality risk in those with established coronary artery disease [29] or heart failure patients [30]. Moreover, Helmersson-Karlqvist et al [31] indicated that increased concentrations of urinary cystatin C were independently associated with a more than 2-fold risk of cardiovascular death. Several underlying mechanisms might be explained the association between elevated cystatin C level and excessive risk of mortality.…”

Section: Discussionmentioning

confidence: 97%

Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis

Luo

Wang

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis

Luo

Wang

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

“…This study focused on the day to day variation of three markers for proximal tubuli damage [6][7][8][9]. Many conditions may cause tubular injury including diabetes, infections, surgery, heart failure, burns, hypercalcemia and administration of drugs such as contrast media, antimicrobials, chemotherapeutics, analgesics and immunosuppressives [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Day-to-day variation of the kidney proximal tubular injury markers urinary cystatin C, KIM1, and NGAL in patients with chronic kidney disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: It is important to know the intraindividual variation of biomarkers to be able to distinguish a change of a biomarker due to the course of the disease from the normal biological variation of the marker. The purpose of this study was to investigate the day-to-day variability of urine markers in nephrology patients. Materials: 23 nephrology patients were included in the study. First morning urine samples were collected daily for ten consecutive days and analyzed for U-cystatin C, U-KIM1, U-NGAL and Ucreatinine. The day-to-day variation was calculated as concentrations of the markers and as creatinine ratios. Values deviating more than the 90 th percentile of the normal intraindividual variation was used to define a disease/treatment specific change.Results: The day-to-day coefficient of variation (CV) for individual patients varied between 9.6 and 100.3% for NGAL (mean 45.6%) and between 8.8 and 107.3% for the NGAL/creatinine ratio (mean 43.8%). The corresponding values for KIM1 were between 10.9 and 60.2% (mean 30.1%) and for the ratio between 8.7 and 59.8% (mean 23.4%) and for cystatin C 3.8-67.4% (mean 25.0%) and for the cystatin C/creatinine ratio 5.9-78.4% (mean 24.8%). Conclusions: The similar intraindividual CV values between the renal tubules damage markers and their corresponding creatinine ratios speaks against using creatinine ratio. Using the 90 th percentiles of the CV values as a limit for clinical change means that NGAL has to change by 83.3%, KIM1 by 45.5% and Cystatin C by 46.3% before the change can be considered clinically significant in patients with chronic kidney disease.

show abstract

“…Since spot urine samples were analyzed, it was reasonable to express results also as u-CYSC/u-CREAT ratio in order to exclude the effect of different hydration states (as it is reported by others) [4,8,[26][27][28]. However, it is future science group www.future-science.com known that in case of tubular damage the excretion of creatinine is also affected which may influence the urinary protein/u-CREAT values [29].…”

Section: Preliminary Reference Ranges Patients' Datamentioning

confidence: 99%

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

et al. 2018

View full text Add to dashboard Cite

Aim: There is no commercially available urinary cystatin-C (u-CYSC) test in the market. Therefore, we optimized and validated an automated immune turbidimetric test for u-CYSC measurements and investigated u-CYSC concentrations in acute and chronic diseases which might lead to renal tubular disorders. Materials & methods: A particle-enhanced immune turbidimetric assay was adapted and validated on a Cobas 8000/c502 analyzer. Urine samples of different patient groups were also analyzed. Results: Our method showed excellent analytical performance. U-CYSC/u-creatinine (u-CREAT) was higher in sepsis-related acute kidney injury group (p < 0.001) compared with controls and to patients with chronic hypertension and Type 2 diabetes. Conclusion: We validated a fast, sensitive, fully automated u-CYSC assay which is ideal for routine use and might be a potential complementary laboratory test to evaluate renal tubular function.

show abstract

Increased urinary cystatin C indicated higher risk of cardiovascular death in a community cohort

Cited by 13 publications

References 46 publications

Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis

Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis

Day-to-day variation of the kidney proximal tubular injury markers urinary cystatin C, KIM1, and NGAL in patients with chronic kidney disease

Novel Automated Immune Turbidimetric Assay for Routine Urinary Cystatin-C Determinations

Contact Info

Product

Resources

About